Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. - Wikidata - awgldk - TriplyDB

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

http://www.wikidata.org/entity/Q35419401

about

Circulating glioma biomarkers Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival.YKL-40 protein correlates with the phenotype of asthma.From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity.Emerging insights into the molecular and cellular basis of glioblastoma.High CHI3L1 expression is associated with glioma patient survival.Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells.Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.Circulating biomarkers of CNS tumors: an update.Systematic review of protein biomarkers of invasive behavior in glioblastoma.Molecular prognostic factors in glioblastoma: state of the art and future challenges.Circulating biomarker panels for targeted therapy in brain tumors.Liquid biopsies in patients with diffuse glioma.Emerging circulating biomarkers in glioblastoma: promises and challenges.Role of chitinase-like proteins in cancer.Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis.Investigation of the Levels of Serum Amyloid A, YKL-40, and Pentraxin-3 in Patients with Familial Mediterranean Fever.Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population.Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma

P2860

Q26830329-9C6A8C58-171D-4507-8474-D2951167F1B9 Q26998561-9E7B4A8E-F477-4B7A-8021-67CC9601662E Q28275702-25F3B67E-62FB-412B-B93D-874824E6EC95 Q28484143-73A8E92E-82CF-4817-A0D9-28DE26A9448B Q33823230-E613007A-B66B-4D2A-AE0A-7E9B8180D68D Q35193405-6390CE9C-B1AC-4E16-BCA0-BEFE1E4FE5F1 Q35828508-F7A6A909-FA45-44C7-94DA-6DC925B170CE Q35914897-91D24667-6E9D-48E0-B9F6-9C87B1C3D31B Q36846738-082B85F4-ADFF-4CE9-9700-85F53B0A06BB Q37191560-3977A3DC-1301-4D6A-B103-F7DB68ED94A1 Q37465420-F194AFC9-8FFA-4B2E-BCF9-9DCABB3DA548 Q37548804-F29A2C6B-57C8-45B3-AE58-667CFF5DEBE6 Q37580396-B5A0EFF4-10FB-45FF-84F7-8DC7380AFB6E Q37733730-BC3830B6-4BAF-4506-87BF-FD36644158E4 Q38095109-FE50C305-9825-41BA-AFCE-B8DE2BF40569 Q38165795-A187D7C0-1FF0-493B-98F2-40FFA2106486 Q38233134-A46BE629-F3C8-48A2-A133-3C4A17FA45E1 Q38252948-17D05C5A-3690-4013-BEE0-614670D13DC6 Q38365590-4F62E616-9297-453C-A53C-8308063514D0 Q38591062-3A3A70D4-A0EB-41DC-B9D1-05461EC9377D Q38687563-4F6259F1-B6D5-4F02-8D64-C38A91F63A5A Q38811271-931C417F-8214-472D-9FB8-83C0468CE8E1 Q38928339-9A2856B3-3E4A-4CB8-9F4C-4776E3C5EA70 Q40082880-4EF90718-3FA9-4ABF-A143-B3BF6CD0BA0C Q41422799-EC7E96BA-BB6B-451D-B541-714C88FA03E6 Q41653273-A80AE6C2-3434-4779-847E-88479D86E665 Q48595349-78CCF6AE-6DC2-4DA1-9E1F-8843D19514E6 Q50293199-633C4FDD-CADF-4014-B863-AC68A4993D35 Q55012452-09189164-D065-4A14-97CA-388370ACED06 Q57146758-11679B6B-F563-4601-8CF1-E4D5BEEB7681

P2860

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

http://www.wikidata.org/entity/Q35419401

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@ast

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@en

type

label

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@ast

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@en

prefLabel

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@ast

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@en

P1433

Q35419401-7582313C-854F-49B2-BC19-390C2742A222

P1476

Q35419401-66BBA044-AD53-4B19-9D67-4E060A317E9F

P2093

Q35419401-051469EB-D269-4014-A7A4-9942E9AB726D

Q35419401-062ED7C9-0763-4B16-A805-B26CBEB5DB2B

Q35419401-0664587E-2BBB-4331-AB5D-F74C55D9889B

Q35419401-0F4F5884-AFAE-4549-A8EE-F73982F9C803

Q35419401-1D1C410F-C4D2-49C5-B38C-704A5399AF0A

Q35419401-527FDED4-2FA7-4CF8-99F1-86A255F66B96

Q35419401-5E8370DE-F86D-4448-A929-361227D7E348

Q35419401-66346666-640F-4AE6-B308-C633A8890833

Q35419401-7AE83989-36D4-4B2A-85F5-DAF3B3BE4D62

Q35419401-7B6F23BC-6437-43DE-BB95-341CE32C1794

P2860

Q35419401-02F062DA-734E-4981-BDD6-CAB4DB9081C7

Q35419401-0EFD5BEA-F9E2-4752-B942-F1F1157F2B4E

Q35419401-127C645C-28D9-40FE-95A6-37F78CAD7D13

Q35419401-173E0851-C092-429C-BC40-2439C47E4F17

Q35419401-1894562C-77C6-49BC-A8EB-9BC05FA28CB6

Q35419401-305C5E0D-9576-4227-BCF1-5CDD1A7337D1

Q35419401-30981BD2-A313-40B1-B1A9-5D2FD93B0072

Q35419401-3769AD2F-B217-4B1C-91B6-F7598023A439

Q35419401-3AEA6898-960E-4154-B509-AD94DE8F408C

Q35419401-43C4846E-E80C-4F25-ADDA-3D196AED57BA

P304

Q35419401-C70541CE-CA84-41B8-A7C5-98C054E0687D

P31

Q35419401-26869464-C3AE-48DD-80EB-9E4F88126667

P356

Q35419401-CC76090D-AFCA-48E7-A504-AC001BF8052B

P433

Q35419401-DED1818C-5303-43FC-859E-3692E8EBDB89

P478

Q35419401-F17FEA33-1F22-459A-ADB9-9C5561C167F9

P577

Q35419401-9183208C-EBCF-4DC0-9FFA-C3AE66E1F474

P5875

Q35419401-9CB072FA-73A9-44CD-9AFB-234432FFAE17

P698

Q35419401-BA7C270D-B7AE-43D9-BD77-2B824E76D258

P932

Q35419401-495154F1-871C-4998-B462-33AFA1AC97A3

P356

P1433

P1476

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

@en

P2093

Adília Hormigo

http://www.w3.org/2001/XMLSchema#string

Andreas F Hottinger

http://www.w3.org/2001/XMLSchema#string

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

Elyn Riedel

http://www.w3.org/2001/XMLSchema#string

Eric C Holland

http://www.w3.org/2001/XMLSchema#string

Fabio M Iwamoto

http://www.w3.org/2001/XMLSchema#string

Jocelynn Dantis

http://www.w3.org/2001/XMLSchema#string

Katherine S Panageas

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

Lisa M DeAngelis

http://www.w3.org/2001/XMLSchema#string

P2860

IDH1 and IDH2 mutations in gliomas

MGMT gene silencing and benefit from temozolomide in glioblastoma.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.

An overview of methods for the analysis of longitudinal data.

Response criteria for glioma.

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Ca

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

P304

1244-1251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOR117

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51562113

http://www.w3.org/2001/XMLSchema#string

P698

21831900

http://www.w3.org/2001/XMLSchema#string

P932

3199155

http://www.w3.org/2001/XMLSchema#string